Personalized medicine using DNA biomarkers: a review
Open Access
- 1 July 2012
- journal article
- review article
- Published by Springer Nature in Human Genetics
- Vol. 131 (10) , 1627-1638
- https://doi.org/10.1007/s00439-012-1188-9
Abstract
Biomarkers are of increasing importance for personalized medicine, with applications including diagnosis, prognosis, and selection of targeted therapies. Their use is extremely diverse, ranging from pharmacodynamics to treatment monitoring. Following a concise review of terminology, we provide examples and current applications of three broad categories of biomarkers—DNA biomarkers, DNA tumor biomarkers, and other general biomarkers. We outline clinical trial phases for identifying and validating diagnostic and prognostic biomarkers. Predictive biomarkers, more generally termed companion diagnostic tests predict treatment response in terms of efficacy and/or safety. We consider suitability of clinical trial designs for predictive biomarkers, including a detailed discussion of validation study designs, with emphasis on interpretation of study results. We specifically discuss the interpretability of treatment effects if a large set of DNA biomarker profiles is available and the number of therapies is identical to the number of different profiles.Keywords
This publication has 47 references indexed in Scilit:
- Risk estimation and risk prediction using machine-learning methodsHuman Genetics, 2012
- Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected PersonsClinical Infectious Diseases, 2011
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor TherapyJournal of Clinical Oncology, 2011
- Genomewide Association Studies and Assessment of the Risk of DiseaseNew England Journal of Medicine, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit AllJournal of Biopharmaceutical Statistics, 2009
- Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyondBritish Journal of Cancer, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Genome-based prediction of common diseases: advances and prospectsHuman Molecular Genetics, 2008
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001